Search Result

Results for "

myeloid leukemia,

" in MedChemExpress (MCE) Product Catalog:

By Targets:	BMI1 (1) 5-HT Receptor (1) ACSL Family (1) ADC Antibody (4) ADC Payload (2) Akt (36) Aldehyde Dehydrogenase (ALDH) (2) AMPK (6) Amyloid-β (1) Anaplastic lymphoma kinase (ALK) (2) Antibiotic (4) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (251) Arenavirus (1) ATF6 (1) Atg8/LC3 (5) ATM/ATR (1) ATP Synthase (1) ATTECs (1) Aurora Kinase (6) Autophagy (23) Bacterial (7) Bcl-2 Family (46) Bcr-Abl (45) Biochemical Assay Reagents (6) Btk (2) c-Fms (1) c-Kit (9) c-Met/HGFR (1) c-Myc (18) C-type Lectin-like Receptors (CTLRs) (1) Calcium Channel (1) Calmodulin (1) Casein Kinase (10) Caspase (36) CD28 (1) CD3 (5) CD44 (1) CD47 (2) CDK (24) Ceramidase (2) Checkpoint Kinase (Chk) (4) Cholinesterase (ChE) (1) ClpP (1) COX (1) Creatine Kinase (1) Cuproptosis (1) CXCR (6) Cytochrome P450 (1) Deubiquitinase (2) Dihydroorotate Dehydrogenase (9) Discoidin Domain Receptor (1) DNA Alkylator/Crosslinker (2) DNA Methyltransferase (8) DNA-PK (1) DNA/RNA Synthesis (18) Drug Derivative (8) Drug Intermediate (2) Drug Isomer (5) Drug Metabolite (9) Drug-Linker Conjugates for ADC (1) DYRK (3) E1/E2/E3 Enzyme (8) E3 Ligase Ligand-Linker Conjugates (2) EGFR (2) Endogenous Metabolite (17) Enolase (1) Environmental Pollutants (4) Epigenetic Reader Domain (58) ERK (14) Estrogen Receptor/ERR (1) Eukaryotic Initiation Factor (eIF) (5) FAK (2) Fat Mass and Obesity-associated Protein (FTO) (6) Fc Receptor (FcR) (2) Ferroptosis (4) FGFR (3) FLT3 (86) Fluorescent Dye (4) Fungal (7) Furin (1) FXR (1) G protein-coupled Bile Acid Receptor 1 (1) G2A (GPR132) (2) Glutathione Peroxidase (2) Glutathione S-transferase (1) GSK-3 (9) Hapten (1) HDAC (29) Heme Oxygenase (HO) (1) HIF/HIF Prolyl-Hydroxylase (4) Hippo (MST) (1) Histamine Receptor (10) Histone Acetyltransferase (6) Histone Demethylase (21) Histone Methyltransferase (9) HIV (1) HOXA (1) HSP (10) Hsp-targeting Chimeras (1) HyT (1) IFNAR (1) IKK (2) IKZF Family (5) IMPDH (1) Influenza Virus (1) Integrin (3) Interleukin Related (13) IRAK (5) Isocitrate Dehydrogenase (IDH) (9) Isotope-Labeled Compounds (12) JAK (18) JNK (1) Keap1-Nrf2 (1) KLF (1) LAG-3 (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (8) LILRB (1) Liposome (1) LPL Receptor (1) MAP4K (1) MARK (2) MDM-2/p53 (13) MEK (1) Methylenetetrahydrofolate Dehydrogenase (MTHFD) (4) METTL3 (5) MHC (1) Microtubule/Tubulin (6) Mitochondrial Metabolism (11) Mitophagy (1) MMP (7) MNK (2) Molecular Glues (19) Monoamine Oxidase (1) Monocarboxylate Transporter (3) Mps1 (2) mTOR (5) Myosin (1) NAMPT (1) Necroptosis (2) NEKs (1) NF-κB (12) NO Synthase (1) NOD-like Receptor (NLR) (2) Notch (2) Nuclear Hormone Receptor 4A/NR4A (1) Oxidative Phosphorylation (4) P-glycoprotein (6) p38 MAPK (25) p62 (5) p97 (2) PACAP Receptor (2) PAI-1 (1) Parasite (6) PARP (14) PDGFR (8) PERK (3) PGE synthase (1) Phosphatase (3) Phosphodiesterase (PDE) (1) PI3K (11) Pim (8) PIN1 (1) Platelet-activating Factor Receptor (PAFR) (1) Polo-like Kinase (PLK) (2) Potassium Channel (1) Prion Protein (3) PROTAC-Linker Conjugates for PAC (2) PROTACs (68) Proteasome (2) Pyroptosis (4) Raf (2) RANKL/RANK (1) RAR/RXR (1) Ras (2) Reactive Oxygen Species (ROS) (22) Reference Standards (20) RET (5) Reverse Transcriptase (1) Ribosomal S6 Kinase (RSK) (1) ROS Kinase (2) Salt-inducible Kinase (SIK) (3) SARS-CoV (4) Scavenger Receptor Class B type I (SR-BI） (1) Ser/Thr Protease (1) SF3B1 (1) SHMT (1) SHP2 (3) Sirtuin (1) Small Interfering RNA (siRNA) (1) SphK (1) Src (6) STAT (43) Stearoyl-CoA Desaturase (SCD) (1) Survivin (2) SWI/SNF Complex (1) TAM Receptor (3) TET Protein (1) TGF-beta/Smad (2) TGF-β Receptor (1) Tie (2) Tim3 (2) TNF Receptor (5) Topoisomerase (4) Transferrin Receptor (2) Transmembrane Glycoprotein (9) Trk Receptor (1) VD/VDR (1) VDAC (1) VEGFR (6) WDR5 (4) Wee1 (3) Wnt (1) YAP (1) YTHDF (2) β-catenin (4)
By Research Areas:	Cancer (626) Cardiovascular Disease (20) Endocrinology (10) Infection (27) Inflammation/Immunology (69) Metabolic Disease (17) Neurological Disease (30)
Click Chemistry:	PROTAC Synthesis (2)
Oligonucleotides:	Aptamers (1) Liposome (1) Antisense Oligonucleotides (3)

639

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Revumenib 10+ Cited Publications SNDX-5613	Epigenetic Reader Domain	Cancer
Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding K_i of 0.149 nM and a cell based IC₅₀ of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .

S63845 Maximum Cited Publications 106 Publications Verification	Bcl-2 Family	Cancer
S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor with a K_d of 0.19 nM for human MCL1 .

MIK665 15+ Cited Publications S-64315	Bcl-2 Family	Cancer
MIK665 (S-64315), derived from S63845, is a myeloid cell leukemia sequence 1 (MCL1) inhibitor . MIK665 has an IC₅₀ of 1.81 nM for MCL1 .

CPS2 1 Publications Verification	PROTACs CDK	Cancer
CPS2 is a first-in-class, highly potent, selective and irreversible PROTAC CDK2 degrader (IC₅₀= 24 nM). CPS2 can be used for the research of acute myeloid leukemia .

SMS121 3 Publications Verification	Scavenger Receptor Class B type I (SR-BI）	Cancer
SMS121 is a CD36 inhibitor with a K_D values of about 5 µM. SMS121 reduces the uptake of lipids and inhibits cell viability in acute myeloid leukemia cells. SMS121 has antitumor activity .

Guadecitabine sodium 10+ Cited Publications SGI-110 sodium; S-110 sodium	DNA Methyltransferase	Cancer
Guadecitabine sodium (SGI-110 sodium) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) .

AK-2292 2 Publications Verification	PROTACs STAT	Cancer
AK-2292 is a potent and selective STAT5 PROTAC degrader, with a DC₅₀ of 0.10 μM. AK-2292 induces degradation of STAT5A/B proteins in vitro and in vivo. AK-2292 can induce tumor regression in acute myeloid leukemia and chronic myeloid leukemia xenograft mouse models . AK-2292 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Iadademstat 5+ Cited Publications ORY-1001	Histone Demethylase Apoptosis	Cancer
Iadademstat (ORY-1001) is a highly potent, orally active and selective LSD1 (KDM1A) inhibitor with antileukemic activity. Iadademstat can be used for relapsed or refractory acute myeloid leukemia research .

Notopterol 2 Publications Verification	Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Notopterol is a coumarin extracted from N. incisum. Notopterol induces apoptosis and has antipyretic, analgesic and anti-inflammatory effects. Notopterol is used for acute myeloid leukemia (AML) .

NSD-IN-2 2 Publications Verification	Histone Methyltransferase	Cancer
NSD-IN-2 is a potent and irreversible NSD inhibitor with inhibitory activity towards members of the NSD family (NSD1/2/3). NSD-IN-2 can be used in research of acute myeloid leukemia .

Nrf2-IN-1 5+ Cited Publications	Keap1-Nrf2	Cancer
Nrf2-IN-1 is an inhibitor of nuclear factor-erythroid 2-related factor 2 (Nrf2). Nrf2-IN-1 is developed for the research of acute myeloid leukemia (AML) .

ML390 1 Publications Verification	Dihydroorotate Dehydrogenase	Cancer
ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models .

Ferumoxytol	Ferroptosis Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology Cancer
Ferumoxytol is an FDA-approved ultrasmall superparamagnetic iron oxide preparation and iron replacement agent that exerts selective activity against leukemia cells with low ferroportin expression. Ferumoxytol increases intracellular iron levels, induces reactive oxygen species (ROS) production via the Fenton reaction, and triggers oxidative stress and cell death. Ferumoxytol reduces disease burden in mouse models and patient-derived leukemia models. As an MRI contrast agent, Ferumoxytol enables imaging of vascular lesions, tumors and lymph nodes. Ferumoxytol can be used in research related to acute myeloid leukemia and blast-phase chronic myeloid leukemia .

Dac590	Fat Mass and Obesity-associated Protein (FTO) Apoptosis	Inflammation/Immunology Cancer
Dac590 is an orally active and selective obesity-associated protein (FTO) inhibitor with an IC₅₀ of 6.06 nM. Dac590 shows highly selective over ALKBH5 and ALKBH3. Dac590 suppresses oncogenic FTO signaling, induces myeloid differentiation, G1-phase cell cycle arrest, and apoptosis in acute myeloid leukemia (AML) cells. Dac590 inhibits xenograft tumor growth and prolongs survival in acute myeloid leukemia mouse models with no observed toxicity. Dac590 can be used for the research of AML .

PD166326	Src Bcr-Abl p38 MAPK	Cancer
PD166326 is an orally active tyrosine kinase inhibitor with a IC₅₀ of 8 nM against abl tyrosine kinase and a IC₅₀ of 6 nM against src tyrosine kinase. PD166326 blocks Bcr/Abl kinase activity. PD166326 inhibits Bcr/Abl-dependent proliferation and cell cycle progression. PD166326 reduces peripheral blood granulocytosis, alleviates splenomegaly and prolongs survival in a mouse model of chronic myeloid leukemia. PD166326 can be used in research related to chronic myeloid leukemia .

Kevetrin hydrochloride 4 Publications Verification 4-Isothioureidobutyronitrile hydrochloride; thioureidobutyronitrile hydrochloride; thioureido butyronitrile hydrochloride	MDM-2/p53 Apoptosis	Cancer
Kevetrin hydrochloride is a potent activator of p53, induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. Kevetrin a preferential cytotoxic activity against blast cells .

TIM-3-IN-2	Tim3 IFNAR	Cancer
TIM-3-IN-2 is a TIM-3 inhibitor. TIM-3-IN-2 blocks the interactions of TIM-3 with PtdSer, CEACAM1 and Gal-9, and inhibits the immunosuppressive function of TIM-3. TIM-3-IN-2 restores IFNγ release from peripheral blood mononuclear cells. TIM-3-IN-2 inhibits the proliferation of acute myeloid leukemia cells. TIM-3-IN-2 can be used for the research of acute myeloid leukemia .

MRT-10350	Molecular Glues Src	Infection Cancer
MRT-10350 (Compound 2) is a cereblon-based HCK molecular glue degrader. MRT-10350 can be used for cancers like chronic myeloid leukemia and HIV-1 infections research .

Rohinitib 1 Publications Verification	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
Rohinitib is a potent and specific eIF4A inhibitor. Rohinitib induces cell apoptosis of acute myeloid leukemia (AML) cell lines and reduces the leukemia burden of AML xenograft model. Rohinitib can be used for the research of AML .

UM4118	Cuproptosis Mitochondrial Metabolism	Cancer
UM4118 is a potent copper-selective non-genotoxic copper ionophore that induces cuproptosis in acute myeloid leukemia cells. UM4118 exhibits stronger activity against SF3B1G12C mutant acute myeloid leukemia cells. UM4118 transports extracellular copper into cells, elevates intracellular and mitochondrial copper levels, and triggers lipoylated DLAT aggregation, proteotoxic stress, iron-sulfur cluster protein depletion, reduced lipoylated protein levels, and maximal mitochondrial respiratory damage. UM4118 cytotoxicity can be enhanced by supplementation with extracellular copper, abolished by copper chelation, and shows synthetic lethal effects in the absence of iron-sulfur cluster biosynthesis/transport genes. UM4118 can be used for the study of acute myeloid leukemia .

IOX5	HIF/HIF Prolyl-Hydroxylase Apoptosis	Cancer
IOX5 is a selective prolyl hydroxylase (PHD) inhibitor with an IC₅₀ of 0.19 μM for PHD2. IOX5 stabilizes HIF-1α in acute myeloid leukemia (AML) cells, inhibits cell proliferation and induces apoptosis. IOX5 has anti-leukemia activity .

TFMB-(R)-2-HG 3 Publications Verification	Estrogen Receptor/ERR Histone Demethylase Fat Mass and Obesity-associated Protein (FTO)	Cancer
TFMB-(R)-2-HG is a cell membrane-permeable (R)-2-HG and acute myeloid leukemia (AML) oncogenic factor. TFMB-(R)-2-HG competitively inhibits α-ketoglutarate-dependent dioxygenases such as KDM2B and FTO. TFMB-(R)-2-HG impairs cell differentiation in response to Estrogen withdrawal. TFMB-(R)-2-HG is used in acute myeloid leukemia and glioma research .

IST5-002 1 Publications Verification N6-Benzyladenosine-5'-phosphate	STAT Apoptosis	Cancer
IST5-002, a potent Stat5a/b inhibitor, selectively inhibits transcriptional activity of Stat5a/b (IC₅₀s: 1.5 μM for Stat5a, 3.5 μM for Stat5b). IST5-002 inducs cell apoptotic and death of prostate cancer cells and chronic myeloid leukemia (CML) cells. IST5-002 can be used in the research of prostate cancer and chronic myeloid leukemia (CML) .

CTX1 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
CTX1 is a p53 activator that overcomes HdmX-mediated p53 repression. CTX1 exhibits potent anti-cancer activity in a mouse acute myeloid leukemia (AML) model system .

6-Aminochrysene 6-Chrysenamine	Drug Derivative	Inflammation/Immunology Cancer
6-Aminochrysene (6-Aminochrysene) is an aromatic amine used as a chemotherapeutic agent in the treatment of splenomegaly, myeloid leukemia, and breast cancer. 6-Aminochrysene is activated by CYP450 in rat liver .

Dihydroevocarpine	mTOR	Cancer
Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the mTORC1/2 activity .

SIAIS100 TFA	PROTACs Bcr-Abl	Cancer
SIAIS100 TFA is a potent BCR-ABL PROTAC degrader with an DC₅₀ value of 2.7 nM. SIAIS100 TFA can be used to research chronic myeloid leukemia (CML) .

Cytarabine-daunorubicin CPX 351; Daunorubicin-Cytarabine Liposome	Liposome Drug Derivative	Cardiovascular Disease Cancer
Cytarabine-daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine (HY-13605) and Daunorubicin (HY-13062A) at a fixed synergistic molar ratio of 5:1. Cytarabine-daunorubicin improves secondary acute myeloid leukemia. Cytarabine-daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia .

MTHFD2-IN-5	Methylenetetrahydrofolate Dehydrogenase (MTHFD)	Cancer
MTHFD2-IN-5 (Compound 16e) is a selective MTHFD2 inhibitor with an IC₅₀ of 66 nM. MTHFD2-IN-5 selectively inhibits MTHFD2. MTHFD2-IN-5 exhibits anticancer activity against acute myeloid leukemia. MTHFD2-IN-5 acts synergistically with Alimta to inhibit the proliferation of acute myeloid leukemia cells .

Guadecitabine SGI-110	DNA Methyltransferase	Cancer
Guadecitabine (SGI-110) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) .

CPTH6 hydrobromide	Apoptosis	Cancer
CPTH6 hydrobromide is a thiazole derivative which activates apoptotic program and increases autophagic features in human acute myeloid leukemia cell lines. CPTH6 can be used for cancer research .

HDAC-IN-27 dihydrochloride	Apoptosis HDAC	Cancer
HDAC-IN-27 dihydrochloride (Compound 11h) is a potent, orally active class I HDAC-selective inhibitor with IC₅₀ values ranging from 0.43 to 3.01 nM against HDAC1-3. HDAC-IN-27 dihydrochloride exhibits both in vivo and in vitro antitumor activity. HDAC-IN-27 dihydrochloride demonstrates significant anti-proliferative activity against acute myeloid leukemia (AML) cell lines by inducing apoptosis and histone acetylation (AcHH3 and AcHH4). HDAC-IN-27 dihydrochloride can be used for research in acute myeloid leukemia (AML) .

HDAC-IN-27	HDAC Apoptosis	Cancer
HDAC-IN-27 (Compound 11h) is a potent, orally active class I HDAC-selective inhibitor with IC₅₀ values ranging from 0.43 to 3.01 nM against HDAC1-3. HDAC-IN-27 exhibits both in vivo and in vitro antitumor activity. HDAC-IN-27 demonstrates significant anti-proliferative activity against acute myeloid leukemia (AML) cell lines by inducing apoptosis and histone acetylation (AcHH3 and AcHH4). HDAC-IN-27 can be used for research in acute myeloid leukemia (AML) .

hDHODH-IN-5	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
DHODH-IN-7 is a human dihydroorotate dehydrogenase (DHODH) inhibitor, with an IC₅₀ of 0.91 μM. DHODH-IN-7 induces differentiation in acute myeloid leukemia .

S1g-10	HSP Bcl-2 Family	Cancer
S1g-10 is a Hsp70/Bim inhibitor, and shows antitumor activity in chronic myeloid leukemia cells .

P0064	Apoptosis FLT3	Cancer
P0064 is a selective inhibitor targeting the PR domain of PRDM16. P0064 selectively reduces proliferation and survival of FLT3-ITD+ leukemia cells and induces cell apoptosis. P0064 is promising for research of acute myeloid leukemia (AML) .

DGN462	DNA Alkylator/Crosslinker ADC Payload	Cancer
DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML). DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .

2-Thiooxamic acid ethyl ester	Biochemical Assay Reagents	Cancer
2-Thiooxamic acid ethyl ester is an organic compound containing thiocarbonyl and ethyl ester groups. 2-Thiooxamic acid ethyl ester can be used in the study of cancer (such as chronic myeloid leukemia, breast cancer, etc.) .

CM-1758	HDAC	Cancer
CM-1758 is a histone deacetylase (HDAC) inhibitor. CM-1758 inhibits tumor growth in vivo. CM-1758 induces acetylation of non-histone proteins in acute myeloid leukemia cells .

DHODH-IN-17	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor (IC₅₀=0.40 μM). DHODH-IN-17 can be used for theresearch of acute myeloid leukemia (AML) .

JNJ-4355 JNJ-78394355	Bcl-2 Family	Cancer
JNJ-4355, a chemical probe, is a highly potent MCL-1 (myeloid cell leukemia-1) inhibitor, with K_I of 18 pM. JNJ-4355 shows antitumor activity .

IMPDH II/HDAC1-IN-1	IMPDH HDAC	Cancer
IMPDH II/HDAC1-IN-1 (Compound C12) is an orally active, selective dual IMPDH II/HDAC1 inhibitor, with an IC₅₀ of 84.69 nM against hIMPDH II and an IC₅₀ of 81.75 nM against HDAC1. IMPDH II/HDAC1-IN-1 inhibits the proliferation of chronic myeloid leukemia cells. IMPDH II/HDAC1-IN-1 can be used for the research of chronic myeloid leukemia .

SIAIS100	PROTACs Bcr-Abl	Cancer
SIAIS100 is a potent BCR-ABL PROTAC degrader with an DC₅₀ value of 2.7 nM. SIAIS100 can be used to research chronic myeloid leukemia (CML) .

ABD-3001	Aldehyde Dehydrogenase (ALDH)	Cancer
ABD-3001 is an inhibitor of ALDH1. ABD-3001 can be studied in research on refractory/relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome .

HSN748	FLT3 Bcr-Abl RET PDGFR MNK	Cancer
HSN748 is a Ponatinib (HY-12047) analogue and a multikinase inhibitor. HSN748 has inhibitory activity on FLT3, ABL1, RET, PDGFRα/β, MNK1, MNK2 and other kinases. HSN748 can inhibit the growth of chronic myeloid leukemia and acute myeloid leukemia cell lines and can be used in the study of leukemia .

CXL 017	Calcium Channel	Cancer
CXL 017 is a sarco/endoplasmic reticulum Ca ²⁺-ATPase (SERCA) inhibitor. CXL 017 can inhibit the ATPase activity of SERCA by competing with ATP for binding. CXL 017 exhibits selective cytotoxicity against multidrug-resistant acute myeloid leukemia cells HL60/MX2. CXL 017 can be used in the research of tumors such as multidrug-resistant acute myeloid leukemia .

Cat. No.	Product Name	Type

HY-100575

Acriflavine

5+ Cited Publications

Acriflavinium chloride 3,6-Acridinediamine mix

Fluorescent Dyes

Acriflavine (Acriflavinium chloride) is a fluorescent acridine dye that can be used to label nucleic acid. Acriflavine is an antiseptic agent. Acriflavine is a potent HIF-1 inhibitor that prevents the dimerization of HIF-1α and HIF-1β subunits. Acriflavine inhibits the interaction between monocarboxylate transporter 4 (MCT4) and Basigin. Acriflavine is used in cancer research, such as breast cancer, brain tumor and chronic myeloid leukemia. Acriflavine is a potent papain-like protease (PLpro) inhibitor, which inhibits SARS-CoV-2 .

HY-D3185

AlDeSense AM

Fluorescent Dyes

AlDeSense AM is a cell-permeable ALDH1A1-selective fluorescent reporter. AlDeSense AM is oxidized by ALDH1A1, which eliminates photoinduced electron transfer quenching and enhances the fluorescent signal. AlDeSense AM can be used to detect cells with cancer stem cell properties, as well as to monitor the plasticity of cancer stem cells in cell culture systems and animal models. AlDeSense AM is applicable to the study of cancers associated with cancer stem cells, including chronic myeloid leukemia, melanoma, and breast cancer .

HY-100575R

Acriflavine (Standard)

Acriflavinium chloride 3,6-Acridinediamine mix (Standard)

Fluorescent Dyes

Acriflavine (Standard) is the analytical standard of Acriflavine (HY-100575). This product is intended for research and analytical applications. Acriflavine (Acriflavinium chloride) is a fluorescent acridine dye that can be used to label nucleic acid. Acriflavine is an antiseptic agent. Acriflavine is a potent HIF-1 inhibitor that prevents the dimerization of HIF-1α and HIF-1β subunits. Acriflavine inhibits the interaction between monocarboxylate transporter 4 (MCT4) and Basigin. Acriflavine is used in cancer research, such as breast cancer, brain tumor and chronic myeloid leukemia. Acriflavine is a potent papain-like protease (PLpro) inhibitor, which inhibits SARS-CoV-2 .

HY-12292G

IM-12

Fluorescent Dyes

IM-12 GMP is IM-12 (HY-12292) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IM-12 is an orally active anti-inflammatory agent that targets and inhibits the NF-κB and STAT3 signaling pathways. IM-12 activates the Wnt signaling pathway and promotes the nuclear translocation of β-catenin by inhibiting GSK3β, while also blocking the tyrosine kinase activity of p210BCR/ABL. IM-12 reduces the levels of IL-6, IL-17, NO, prostaglandin E2, iNOS and COX-2, and induces ER stress, Ca ²⁺ release, autophagy and apoptosis. IM-12 is heat-sensitive and does not induce autophagy in IM-resistant p210BCR/ABL ^T315I mutant cells. IM-12 is also a component of the 5iLA medium used for naive pluripotent stem cell research. IM-12 has been applied in studies related to carrageenan (HY-125474)-induced hind paw edema, TNBS-induced colitis, and acute and chronic myeloid leukemia .

Cat. No.	Product Name	Type

HY-Y1103

Iron(II) sulfate heptahydrate, 99%

1 Publications Verification

Ferrous sulfate heptahydrate, 99%

Biochemical Assay Reagents

Iron(II) sulfate heptahydrate, 99% (Ferrous sulfate heptahydrate, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer .

HY-Y1103A

Iron(II) sulfate heptahydrate, for cell culture, 99%

1 Publications Verification

Ferrous sulfate heptahydrate, for cell culture, 99%

Biochemical Assay Reagents

Iron(II) sulfate heptahydrate, for cell culture, 99% (Ferrous sulfate heptahydrate, for cell culture, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, for cell culture, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, for cell culture, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, for cell culture, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer .

HY-78216

2-Thiooxamic acid ethyl ester	Biochemical Assay Reagents
2-Thiooxamic acid ethyl ester is an organic compound containing thiocarbonyl and ethyl ester groups. 2-Thiooxamic acid ethyl ester can be used in the study of cancer (such as chronic myeloid leukemia, breast cancer, etc.) .

HY-12292G

IM-12

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Cyclo(RGDfV) TFA; C(RGDfV) TFA	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .

HY-P3508

PNC-27	MDM-2/p53	Cancer
PNC-27, a chimeric p53-penetratin peptide binds to HDM-2 in a p53 peptide-like structure, induces selective membrane-pore formation and leads to cancer cell lysis. PNC-27 is an anticancer peptide. PNC-27 can be used in acute myeloid leukemia research .

HY-P3508A

PNC-27 acetate	MDM-2/p53	Cancer
PNC-27 acetate, a chimeric p53-penetratin peptide binds to HDM-2 in a p53 peptide-like structure, induces selective membrane-pore formation and leads to cancer cell lysis. PNC-27 acetate is an anticancer peptide. PNC-27 acetate can be used in acute myeloid leukemia research .

HY-P11288

ANT308	PACAP Receptor Apoptosis	Cancer
ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the studies of acute myeloid leukemia (AML) and uveal melanoma (UVM) .

HY-P11288A

ANT308 TFA	PACAP Receptor Apoptosis	Cancer
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM) .

HY-P11451

Pentixather	CXCR	Cancer
Pentixather is a radiolabeled peptide that can target CXCR4. Pentixather can disrupt the interaction between leukemic cells and the bone marrow microenvironment by targeting the CXCR4/CXCL12 signaling axis, reduce the retention of leukemic cells in the protective bone marrow niche, and thereby enhance the sensitivity of leukemic cells to treatment. Pentixather can be used for the study of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .

HY-P1613

Cyclo(Arg-Gly-Asp-D-Phe-Val) Cyclo(RGDfV); C(RGDfV)	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .

HY-P11437

GFKQSSKAL	MHC	Cancer
GFKQSSKAL is an e14a2 junctional sequence. GFKQSSKAL binds well to HLA-B8. GFKQSSKAL can be used in the research of chronic myeloid leukemia .

HY-P11705

PUMA2A	Biochemical Assay Reagents	Cancer
PUMA2A is a PUMA BH3-only peptide. PUMA2A can be used as a negative control in Cytochrome C release assays and BH3 profiling. PUMA2A can be used in the research of chronic myeloid leukemia .

Cat. No.	Product Name

HY-K3102

*Human Acute Myeloid* Leukemia Cell Culture Medium**
MCE Human Acute Myeloid Leukemia Cell Culture Medium is specially designed to promote the in vitro growth of primary human acute myeloid leukemia cells.

Cat. No.	Product Name	Target	Research Area	Image

HY-P99014

Cusatuzumab 1 Publications Verification ARGX-110	Fc Receptor (FcR) NF-κB	Inflammation/Immunology Cancer
Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .

HY-P99971

Gemtuzumab	ADC Antibody Transmembrane Glycoprotein	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P99521

Vibecotamab XmAb14045	CD3	Inflammation/Immunology Cancer
Vibecotamab (XmAb14045) is a potent bispecific antibody targeting both CD123 and CD3. Vibecotamab targets T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. Vibecotamab is a full length immunoglobulin molecule. Vibecotamab can be studied in research for diseases such as Myelodysplastic syndrome and acute myeloid leukemia. Recommend Isotype Control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .

HY-P99488

Briquilimab JSP-191; AMG-191	c-Kit	Inflammation/Immunology Cancer
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .

HY-P991558

RO-5429083 RG-7356	Transmembrane Glycoprotein	Cancer
RO-5429083 (RG-7356) is a humanized monoclonal antibody targeting CD44. RO-5429083 binds to the extracellular domain of CD44 and inhibits constitutive EGFR phosphorylation. RO-5429083 suppresses tumor growth in xenograft models and can be used in research related to head and neck squamous cell carcinoma and acute myeloid leukemia .

HY-P99950

Evorpacept ALX148	CD47	Cancer
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-P99272

Ulocuplumab 1 Publications Verification BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody	CXCR	Cancer
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .

HY-P99910

Eluvixtamab AMG-330	CD3 Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Eluvixtamab (AMG-330) is a bispecific T-cell engager. Eluvixtamab binds to CD33 and CD3 on T cells, thereby promoting T cell-mediated cytotoxicity against CD33+ cells. Eluvixtamab can be used in the research of tumors such as relapsed/refractory acute myeloid leukemia .

HY-P991669

IGN523 AML-01	Caspase Apoptosis	Cancer
IGN523 is an anti-CD98 antibody (hCD98, K_D = 0.55 nM). IGN523 induces antibody-dependent cell-mediated cytotoxicity (ADCC) activity, lysosomal membrane permeabilization, and inhibition of essential amino acid transport, ultimately leading to caspase-3 and caspase-7-mediated apoptosis of tumor cells. IGN523 inhibits tumor growth in multiple tumor xenograft models. IGN523 is useful in the research of non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), and other cancers. .

HY-P99958

Vixtimotamab AMV-564; TandAb T564	Transmembrane Glycoprotein	Cancer
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .

HY-P99916

Emirodatamab AMG-427	FLT3 CD3 TNF Receptor	Inflammation/Immunology Cancer
Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of *acute myeloid* leukemia (AML) cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with PD-1** blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases .

HY-P991699

Lixarkitug AZD9829 antibody; INT-020	ADC Antibody Interleukin Related	Cancer
Lixarkitug (AZD9829 antibody; INT-020) is a humanized IgG1κ antibody targeting IL-3Ra/CD123. Lixarkitug can be conjugated with Samrotecan to form the intact ADC molecule lixarkitug samrotecan (AZD9829), which is used in studies of acute myeloid leukemia (AML) . The isotype control corresponding to Lixarkitug is Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P99395

Talacotuzumab 1 Publications Verification JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

HY-P990002

Anti-Mouse CD117/c-Kit Antibody (2B8)	c-Kit	Inflammation/Immunology Cancer
Anti-Mouse CD117/c-Kit Antibody (2B8) is an IgG2b antibody, targeting to mouse CD117/c-Kit. Anti-Mouse CD117/c-Kit Antibody (2B8) reacts with mouse c-Kit (also known as CD117), which is expressed on hematopoietic progenitor cells, mast cells, and acute myeloid leukemia (AML) cells. Anti-Mouse CD117/c-Kit Antibody (2B8) can be used for the detection of flow cytometry, immunofluorescence and immunohistochemistry in cancer and inflammation .

HY-P991665

MEN1112 OBT357NF; OBT357	Transmembrane Glycoprotein	Cancer
MEN1112 (OBT357NF) is a selective humanized monoclonal antibody targeting the Bst1/CD157 antigen (EC₅₀=1 nM). MEN1112 exerts potent antitumor activity against acute myeloid leukemia (AML) cells. MEN1112 is promising for research of hematological malignancies such as AML .

HY-P990905

Bexatamig SAR-443579	Interleukin Related	Cancer
Bexatamig (SAR-443579) is a trifunctional natural killer cell engager targeting IL-3R α/CD123, NKp46/NCR1/CD335 and Fc gamma RIIIA/CD16a. Bexatamig forms a cytolytic synapse between natural killer cells and CD123-positive tumor cells. By activating natural killer cells to induce tumor cell death, Bexatamig effectively reduces the burden of CD123-positive acute myeloid leukemia (AML) blasts. Bexatamig has been granted FDA Fast Track designation, and is primarily investigated for relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and high-risk myelodysplastic syndromes .

HY-P991656

LY-2624587	CXCR Apoptosis p38 MAPK Akt	Cancer
LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting CXCR4. LY-2624587 blocks SDF-1/CXCR4 interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research .

HY-P990164

Anti-Mouse RGMb Antibody (307.9D1)	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Anti-Mouse RGMb Antibody (307.9D1) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse RGMb. Anti-Mouse RGMb Antibody (307.9D1) blocks RGMb binding to PD-L2. Anti-Mouse RGMb Antibody (307.9D1) can be used for the researches of cancer inflammation and immunology, such as acute myeloid leukemia (AML) and graft versus-host disease (GVHD) .

HY-P990928

Mipletamig APVO-436	CD3 Interleukin Related	Inflammation/Immunology Cancer
Mipletamig (APVO-436) is a bispecific CD123 x CD3 monoclonal antibody. Mipletamig simultaneously binds to both CD3-expressing T cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. Mipletamig can be used for the study of acute myeloid leukemia (AML) .

HY-P991425

AT-1413	Transmembrane Glycoprotein	Cancer
AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991648

CSL-360	Interleukin Related	Cancer
CSL-360 is a chimeric unconjugated IgG1 monoclonal antibody targeting CD123. CSL-360 efficiently prevents the binding of IL-3 to CD123, abolishing IL-3 induced cell proliferation. CSL-360 can be used for acute myeloid leukemia (AML) research .

HY-P990901

Aplitabart IGM-8444	TNF Receptor Apoptosis	Inflammation/Immunology Cancer
Aplitabart (IGM-8444) is a a pentameric IgM DR5 agonist antibody with 10 binding sites specific for DR5. Aplitabart multimerizes DR5 to selectively and potently induce tumor cell apoptosis. Aplitabart can be used for the study of lung cancer, breast cancer, cute myeloid leukemia (AML) and low-grade B-cell non-Hodgkin lymphoma (B-NHL) .

HY-P991294

MGTA-117 Antibody	ADC Antibody	Cancer
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .

HY-P992389

IO-202	LILRB	Cancer
IO-202 is a high-affinity LILRB4/ILT3 binder and myeloid checkpoint inhibitor. IO-202 blocks APOE binding and LILRB4 activation to reverse T-cell suppression and enhance T-cell cytotoxicity, while eliminating LILRB4-high-expressing leukemic blasts via ADCC and ADCP mechanisms. IO-202 promotes dendritic cell maturation and antigen presentation, reshapes the phenotype of tumor-associated macrophages, and reduces myeloid-derived suppressor cells. IO-202 is widely applicable to research on relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors .

HY-P992320

BAT-6004	CD47	Cancer
BAT-6004 is a monoclonal antibody that targets CD47 and is a CD47 inhibitor. BAT-6004 can be used in research on acute myeloid leukemia and diffuse large B-cell lymphoma .

HY-P992058

Leukotuximab ART-140; DNP-001; EGX-040	Transmembrane Glycoprotein	Cancer
Leukotuximab (ART-140; EGX-040) is an anti-JL1 mAb and an anti-leukemic agent. Leukotuximab targets the JL1 epitope of CD43 and exerts cytotoxic effects on JL1-positive leukemia cells. Except for thymocytes and some bone marrow mononuclear cells, Leukotuximab causes no damage to most normal tissues. Leukotuximab can be used in the research of acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome .

HY-P992027

CSC012 Antibidy	ADC Antibody	Cancer
CSC012 Antibody is a monoclonal antibody inhibitor targeting IL-1RAP. CSC012 Antibody can be used to synthesize the antibody-drug conjugate (ADC) CSC012. ADV-101 Antibody can be used to research related to acute myeloid leukemia .

HY-P992439

PF-06747143	CXCR	Cancer
PF-06747143 is recombinant anti-human antibody targeting CXCR4. PF-06747143 blocks CXCL12-induced calcium flux, F-actin polymerization, chemotaxis, cell migration, and leukemic cell bone marrow homing. PF-06747143 reduces tumor burden and improves survival in mouse models of hematologic malignancies. PF-06747143 can be used for the research of chronic lymphocytic leukemia, acute myeloid leukemia, and hematologic malignancies .

HY-P992333

CLT030 Antibody	C-type Lectin-like Receptors (CTLRs)	Cancer
CLT030 Antibody is a human monoclonal antibody targeting CLL1/CLEC12A/CD371, with a K_d value of 7.32 nM against human targets. CLT030 Antibody can be used to synthesize the ADC CLT030. It is applicable to research related to acute myeloid leukemia .

HY-P992460

SHR-1702	Tim3	Cancer
SHR-1702 is a monoclonal antibody targeting TIM-3, which specifically binds to and blocks the TIM-3 signaling pathway. SHR-1702 restores the function of immune cells and inhibits the proliferation process of malignant cells. SHR-1702 is mainly used in relevant research on acute myeloid leukemia and myelodysplastic syndromes .

HY-P991998

Anti-Human/Monkey CD16a Antibody (3G8)	Fc Receptor (FcR)	Inflammation/Immunology Cancer
Anti-Human/Monkey CD16a Antibody (3G8) is a monoclonal antibody targeting CD16a. Anti-Human/Monkey CD16a Antibody (3G8) blocks FcγRIII/CD16a, upregulates the metabolic activity of CD16+ cells, downregulates CD87, a poor prognostic marker, and inhibits the engraftment and growth of leukemia cells in acute myeloid leukemia, and rapidly increases platelet counts in immune thrombocytopenia. Anti-Human/Monkey CD16a Antibody (3G8) is applicable to research related to tumor immunology .

HY-P992032

TPP-9476 BAY-943 antibody	Interleukin Related	Cancer
TPP-9476 (BAY-943 antibody) is an anti-human IL3RA (CD123) monoclonal antibody with human IL3RA K_d of 11 nM and cynomolgus monkey IL3RA K_d of 16 nM. TPP-9476 binds specifically to human and cynomolgus monkey IL3RA, undergoes target-dependent internalization into lysosomes of IL3RA-positive cells.TPP-9476 exerts antiproliferative effects in IL3RA-expressing acute myeloid leukemia and classical Hodgkin lymphoma cells, reduces tumor burden, improves survival, and induces complete tumor remission in relevant xenograft mouse models .

Species:	Human (4)
Tag:	His (2) Tag Free (1) Myc (2) GST (1)
Source:	E. coli (4)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P701589

	KMT2D Protein, Human KMT2D; Histone-lysine N-methyltransferase 2D; Lysine N-methyltransferase 2D; ALL1-related protein; myeloid/lymphoid or mixed-lineage leukemia protein 2	Human	E. coli
	KMT2D Protein, a histone methyltransferase, methylates histone H3 'Lys-4' (H3K4), predominantly establishing H3K4me1 marks at active chromatin sites. Integral to chromatin remodeling, it functions as a coactivator for the estrogen receptor, recruited by ESR1, activating transcription. KMT2D's role in depositing specific histone marks at genomic locations underscores its crucial involvement in modulating chromatin structure and gene expression. KMT2D Protein, Human is the recombinant human-derived KMT2D protein, expressed by E. coli , with tag free.

HY-P701590

	KMT2D Protein, Human (GST) KMT2D; Histone-lysine N-methyltransferase 2D; Lysine N-methyltransferase 2D; ALL1-related protein; myeloid/lymphoid or mixed-lineage leukemia protein 2	Human	E. coli
	KMT2D Protein, a histone methyltransferase, methylates histone H3 'Lys-4' (H3K4), predominantly establishing H3K4me1 marks at active chromatin sites. Integral to chromatin remodeling, it functions as a coactivator for the estrogen receptor, recruited by ESR1, activating transcription. KMT2D's role in depositing specific histone marks at genomic locations underscores its crucial involvement in modulating chromatin structure and gene expression. KMT2D Protein, Human (GST) is the recombinant human-derived KMT2D protein, expressed by E. coli , with N-GST labeled tag.

HY-P705952

	Runx1 Protein, Human (His, Myc) Acute myeloid leukemia 1; Acute myeloid leukemia 1 protein; alpha subunit core binding factor; AML 1; AML1; AML1 EVI 1; AML1 EVI 1 fusion protein; Aml1 oncogene; AMLCR 1; AMLCR1; CBF alpha 2; CBF-alpha-2; CBFA 2; CBFA2; Core binding factor alpha 2 subunit; Core binding factor runt domain alpha subunit 2; Core-binding factor subunit alpha-2; EVI 1; EVI1; HGNC; Oncogene AML 1; Oncogene AML-1; OTTHUMP00000108696; OTTHUMP00000108697; OTTHUMP00000108699; OTTHUMP00000108700; OTTHUMP00000108702; PEA2 alpha B; PEA2-alpha B; PEBP2 alpha B; PEBP2-alpha B; PEBP2A2; PEBP2aB; Polyomavirus enhancer binding protein 2 alpha B subunit; Polyomavirus enhancer-binding protein 2 alpha B subunit; Run1; Runt related transcription factor 1; Runt-related transcription factor 1; RUNX 1; Runx1; RUNX1_HUMAN; SL3 3 enhancer factor 1 alpha B subunit; SL3-3 enhancer factor 1 alpha B subunit; SL3/AKV core binding factor alpha B subunit; SL3/AKV core-binding factor alpha B subunit	Human	E. coli

HY-P706118

	Runx3 Protein, Human (His, Myc) Acute myeloid leukemia 2 protein; Acute myeloid leukemia gene 2; AML 2; AML2; CBF alpha 3; CBF-alpha-3; CBFA 3; CBFA3; Core binding factor alpha 3 subunit; core binding factor; Core binding factor runt domain alpha subunit 3; Core binding factor subunit alpha 3; core-binding factor; Core-binding factor subunit alpha-3; Oncogene AML 2; Oncogene AML-2; PEA2 alpha C; PEA2-alpha C; PEBP2 alpha C; PEBP2-alpha C; Pebp2a3; PEBP2aC; Polyomavirus enhancer binding protein 2 alpha C subunit; Polyomavirus enhancer-binding protein 2 alpha C subunit; runt domain alpha subunit 3 ; runt related transcription factor 3; Runt-related transcription factor 3; RUNX 3; Runx3; RUNX3_HUMAN; SL3 3 enhancer factor 1 alpha C subunit; SL3-3 enhancer factor 1 alpha C subunit; SL3/AKV core binding factor alpha C subunit; SL3/AKV core-binding factor alpha C subunit; Transcription factor AML2	Human	E. coli

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (3) Rabbit (5)
Reactivity:	Human (8) Rat (5) Mouse (5)
Application:	IHC-P (6) ICC/IF (7) IP (4) WB (6) FC (3) ELISA (4)
Isotype:	IgG (3) IgG1 (2) IgG/Kappa (2)
Conjugation:	Non-conjugated (8)
Clonality:	Monoclonal (7) Recombinant (2)
Modification:	Unmodified (7)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P88513

	*MLF1 (Myeloid* leukemia factor 1) Antibody (YA8197)** myeloid leukemia factor 1; myeloid leukemia factor 1 variant 1; myeloid leukemia factor 1 variant 2; myeloid leukemia factor 1 variant 3	IHC-P, ICC/IF, FC	Human
	MLF1 (Myeloid leukemia factor 1) Antibody (YA8197) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MLF1 (Myeloid leukemia factor 1).

HY-P88513A

	*MLF1 (Myeloid* leukemia factor 1) Antibody (YA8197)(PBS only)** myeloid leukemia factor 1; myeloid leukemia factor 1 variant 1; myeloid leukemia factor 1 variant 2; myeloid leukemia factor 1 variant 3	IHC-P, ICC/IF, FC	Human
	MLF1 (Myeloid leukemia factor 1) Antibody (YA8197) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MLF1 (Myeloid leukemia factor 1).

HY-P87010

	PICALM Antibody (YA6703) CALM antibody; Clathrin assembly lymphoid myeloid leukemia antibody; Clathrin assembly lymphoid myeloid leukemia protein antibody; CLTH antibody; LAP antibody; Phosphatidylinositol-binding clathrin assembly protein antibody; PICAL_HUMAN antibody; PICALM antibody;	WB, IHC-P	Human, Mouse, Rat
	PICALM Antibody (YA6703) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PICALM.

HY-P86201

	RUNX1 Antibody (YA5893) RUNX1; AML1; CBFA2; Runt-related transcription factor 1; Acute myeloid leukemia 1 protein; Core-binding factor subunit alpha-2; CBF-alpha-2; Oncogene AML-1; Polyomavirus enhancer-binding protein 2 alpha B subunit; PEA2-alpha B; PEBP2-alpha	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	RUNX1 Antibody (YA5893) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RUNX1.

HY-P85360

	RUNX1 Antibody (YA5052) RUNX1; AML1; CBFA2; Runt-related transcription factor 1; Acute myeloid leukemia 1 protein; Core-binding factor subunit alpha-2; CBF-alpha-2; Oncogene AML-1; Polyomavirus enhancer-binding protein 2 alpha B subunit; PEA2-alpha B; PEBP2-alpha	WB, ICC/IF, ELISA	Human
	RUNX1 Antibody (YA5052) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to RUNX1.

HY-P86177

	MCL1 Antibody (YA5869) MCL1; BCL2L3; Induced myeloid leukemia cell differentiation protein Mcl-1; Bcl-2-like protein 3; Bcl2-L-3; Bcl-2-related protein EAT/mcl1; mcl1/EAT	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	MCL1 Antibody (YA5869) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MCL1.

HY-P85269

	MCL1 Antibod (YA4961) MCL1; BCL2L3; Induced myeloid leukemia cell differentiation protein Mcl-1; Bcl-2-like protein 3; Bcl2-L-3; Bcl-2-related protein EAT/mcl1; mcl1/EAT	WB, ICC/IF, IP, FC	Human, Mouse, Rat
	MCL1 Antibody (YA4961) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to MCL1.

HY-P86399

	RUNX2 Antibody (YA6091) RUNX2; AML3; CBFA1; OSF2; PEBP2A; Runt-related transcription factor 2; Acute myeloid leukemia 3 protein; Core-binding factor subunit alpha-1; CBF-alpha-1; Oncogene AML-3Osteoblast-specific transcription factor 2; OSF-2; Polyomavirus enhancer-binding protein 2 alpha A subunit; PEA2-alpha A; PEBP2-alpha A; SL3-3 enhancer factor 1 alpha A subunit; SL3/AKV core-binding factor alpha A subunit	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	RUNX2 Antibody (YA6091) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RUNX2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-148813

AK-2292 2 Publications Verification		PROTAC Synthesis
AK-2292 is a potent and selective STAT5 PROTAC degrader, with a DC₅₀ of 0.10 μM. AK-2292 induces degradation of STAT5A/B proteins in vitro and in vivo. AK-2292 can induce tumor regression in acute myeloid leukemia and chronic myeloid leukemia xenograft mouse models . AK-2292 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-150251

SD-91 STAT3 degrader-2		PROTAC Synthesis
SD-91 (STAT3 degrader-2), a product of the hydrolysis of SD-36 (HY-129602), is a selective PROTAC-based STAT3 degrader with a K_i of 5.5 nM. SD-91 displays >300-fold selectivity over other STAT family protein members. SD-91 potently induces degradation of STAT3 protein in cells. SD-91 has anticancer effects, such as myeloid leukemia, lymphoma (Pink: ligand for target protein (HY-150895); Black: linker; Blue: E3 ligase ligand; E3 ligase ligand+linker: HY-176506) .

Cat. No.	Product Name		Classification

HY-145729

Danvatirsen AZD9150		Antisense Oligonucleotides
Danvatirsen (AZD9150) is an antisense oligonucleotide targeting STAT3. Danvatirsen reduces the viability and promotes apoptosis of leukemia cell lines. Danvatirsen inhibits the expression of endogenous STAT3 and its downstream target genes, and reduces the proliferation and tumorigenicity of neuroblastoma and lymphoma cells. Danvatirsen inhibited tumor growth in mouse models of neuroblastoma, lymphoma, and non-small cell lung cancer. Danvatirsen achieves STAT3 mRNA and protein depletion in a mouse model of epidermoid carcinoma. Danvatirsen can be used in research related to lymphoma, myelodysplastic syndrome, acute myeloid leukemia, neuroblastoma and non-small cell lung cancer .

HY-145729A

Danvatirsen sodium AZD9150 sodium		Antisense Oligonucleotides
Danvatirsen sodium (AZD9150 sodium) is an antisense oligonucleotide targeting STAT3. Danvatirsen sodium reduces the viability and promotes apoptosis of leukemia cell lines. Danvatirsen sodium inhibits the expression of endogenous STAT3 and its downstream target genes, and reduces the proliferation and tumorigenicity of neuroblastoma and lymphoma cells. Danvatirsen sodium inhibited tumor growth in mouse models of neuroblastoma, lymphoma, and non-small cell lung cancer. Danvatirsen sodium achieves STAT3 mRNA and protein depletion in a mouse model of epidermoid carcinoma. Danvatirsen sodium can be used in research related to lymphoma, myelodysplastic syndrome, acute myeloid leukemia, neuroblastoma and non-small cell lung cancer .

HY-160952

Cytarabine-daunorubicin CPX 351; Daunorubicin-Cytarabine Liposome		Liposome
Cytarabine-daunorubicin (CPX 351) is a Liposomal formulation prepared from Cytarabine (HY-13605) and Daunorubicin (HY-13062A) at a fixed synergistic molar ratio of 5:1. Cytarabine-daunorubicin improves secondary acute myeloid leukemia. Cytarabine-daunorubicin can be used in research related to secondary acute myeloid leukemia, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia .

HY-153495

Prexigebersen BP1001		Antisense Oligonucleotides
Prexigebersen (BP1001) is an antisense oligonucleotide targeting Bcl-2 and Grb2. Prexigebersen exhibits antileukemic activity in cell models. Prexigebersen induces apoptosis (apoptosis), cell cycle arrest and ROS production in leukemia cells. Prexigebersen inhibits Grb2 expression, thereby suppressing tumor growth and survival. Prexigebersen can be used in studies related to acute myeloid leukemia .

HY-177821

CD117/c-Kit aptamer sodium		Aptamers
CD117/c-Kit aptamer sodium is a single-strand DNA aptamer specific for the biomarker CD117, which is highly expressed on acute myeloid leukemia (AML) cells.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

myeloid leukemia,

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products